For Registration click here For Scientific Program click here Program Highlights Translational Research Program Surrounding Cannabis and Cannabinoids Carolyn Baglole, McGill University, Canada The Endocannabinoid System as a Novel Therapeutic Target for Pain and CNS Disorders: Can the Promise be Realised? David Finn, National University of Ireland, Ireland Psychosocial Consequences of Regular Recreational Cannabis Use Eva Hoch, Ludwig Maximilian University, Germany Position of the European Pain Federation EFIC® on Appropriate Use of Cannabis‐Based Medicines and Medical Cannabis for Chronic Pain Management Bart Morlion, European Pain Federation EFIC, Belgium State of Medical Cannabis Education in the EU and the World Gregor Zorn, European Cannabinoid Therapy Association - ECTA, Slovenia Long-Term Treatment with Cannabis in Fibromyalgia Piercarlo Sarzi-Puttini, ASST Fatebenefratelli-Sacco, University of Milan, Italy Systematic Review [...]
Lire la suiteIntranasal Ketamine Succeeds for Resistant Depression in Phase 3 Trial Deborah Brauser May 11, 2018 https://www.medscape.com/viewarticle/896510 NEW YORK — Administering intranasal esketamine (Janssen) plus an antidepressant is safe, effective, and well tolerated in adult patients with treatment-resistant depression (TRD), a new phase 3 trial suggests. Dr Vanina Popova In the global study, those who received a newly initiated oral antidepressant combined with esketamine nasal spray (56 or 84 mg) showed a 4-point greater improvement from baseline to 4 weeks on the Montgomery-Åsberg Depression Rating Scale (MADRS) total score than those who received an antidepressant plus placebo, meeting the study's primary endpoint. In addition, the response rate was nearly 70% [...]
Lire la suiteCANNABIS ET CANNABIDIOL : Éléments de Compréhension Dr Sarah Lejczak La Lettre du RESPADD, 35, avril 2019 Depuis 5000 ans, le cannabis ruderalids, sativa ou indica est utilisé dans la pharmacopée humaine de manière informelle pour ses différentes propriétés antihémétiques, antiépileptiques, antispastiques, antalgiques, anxiolytiques, antihypertensives, etc. (1). Suite à son introduction dans l’arsenal pharmaceutique moderne au XIXème siècle et les dérives d’utilisation récréative au cours du XXème siècle, son utilisation a été interdite et reste très controversée de nos jours. Des extraits cannabinoïdes (2) (Delta-9-tetrahydrocannabinol (Δ-9-THC), cannabidiol (CBD) et cannabinol (CBN) majoritairement) de la plante ou fabriqués synthétiquement sont utilisés depuis 1985 en tant que médicaments. [...]
Lire la suite3,4-Methylenedioxymethamphetamine assisted psychotherapy for treatment of chronic posttraumatic stress disorder : A randomized phase 2 controlled trial Marcela Ot’alora G, Jim Grigsby, Bruce Poulter1, Joseph W Van Derveer III, Sara Gael Giron, Lisa Jerome, Allison A Feduccia, Scott Hamilton, Berra Yazar-Klosinski, Amy Emerson, Michael C Mithoefer and Rick Doblin Journal of Psychopharmacology, 2018, 1-13 Doi : 10.1177/0269881118806297 Abstract Background : Posttraumatic stress disorder often does not resolve after conventional psychotherapies or pharmacotherapies. Pilot studies have reported that 3,4-methylenedioxymethamphetamine (MDMA) combined with psychotherapy reduces posttraumatic stress disorder symptoms. Aims : This pilot dose response trial assessed efficacy and safety of MDMA-assisted psychotherapy across multiple therapy teams. Methods : [...]
Lire la suiteChapter : The endocannabinoid system in Fragile X Syndrome Henry G. S. Martin, Daniela Neuhofer and Olivier J.J. Manzoni Fragile X Syndrome : From Genetics to Targeted Treatment, 2017, Pages 241-259 DOI: 10.1016/B978-0-12-804461-2.00012-3 Addresses: INSERM U901, INMED and UMR S901, Aix-Marseille University Marseille 13009, France. Abstract : Endocannabinoid signaling is a finely tuned system of molecules and lipid messengers that modulate neurotransmission in a rapid and sustained manner at many central synapses. The endocannabinoid system is important for many brain activities, but is also implicated in several neuropsychiatric disorders. In this chapter we discuss emerging evidence of dysfunction in endocannabinoid signaling in Fragile X Syndrome from the Fmr1 knockout mouse model. [...]
Lire la suiteOvercoming the Bell‐Shaped Dose‐Response of Cannabidiol by Using Cannabis Extract Enriched in Cannabidiol Ruth Gallily, Zhannah Yekhtin, Lumír Ondřej Hanuš Pharmacology & Pharmacy, 2015, 6, 75-85 http://dx.doi.org/10.4236/pp.2015.62010 Abstract : Cannabidiol (CBD), a major constituent of Cannabis, has been shown to be a powerful anti inflammatory and anti‐anxiety drug, without exerting a psychotropic effect. However, when given either intraperitoneally or orally as a purified product, a bell‐shaped dose‐response was observed, which limits its clinical use. In the present study, we have studied in mice the anti‐inflammatory and anti nociceptive activities of standardized plant extracts derived from the Cannabis sativa L., clone 202, which is highly enriched [...]
Lire la suiteLegalizing and Regulating Marijuana in Canada: Review of Potential Economic, Social, and Health Impacts Mohammad Hajizadeh International Journal of Health Policy and Management, 2016, 5, 8, 453–456. doi:10.15171/ijhpm.2016.63 Abstract : Notwithstanding a century of prohibition, marijuana is the most widely used illicit substance in Canada. Due to the growing public acceptance of recreational marijuana use and ineffectiveness of the existing control system in Canada, the issue surrounding legalizing this illicit drug has received considerable public and political attentions in recent years. Consequently, the newly elected Liberal Government has formally announced that Canada will introduce legislation in the spring of 2017 to start legalizing and regulating [...]
Lire la suiteCannabis legalization in Canada: how might ‘strict’ regulation impact youth? Tara Marie Watson & Patricia G. Erickson DRUGS: EDUCATION, PREVENTION AND POLICY, 2018 https://doi.org/10.1080/09687637.2018.1482258 EDITORIAL Cannabis legalization in Canada: how might ‘strict’ regulation impact youth? Canada is on course to become, in October 2018, the second country in the world, after Uruguay, to federally legalize cannabis for recreational use. Prime Minister Justin Trudeau’s Liberal government has set out to achieve several objectives with this major drug policy reform, including ‘[to] Protect young Canadians by keeping marijuana out of the hands of children and youth’ (Government of Canada, 2016). While protecting the health and safety of [...]
Lire la suiteCannabis legalization in the provinces and territories : missing opportunities to effectively educate youth ? Tara Marie Watson, Jenna Valleriani, Elaine Hyshka & Sergio Rueda Canadian Journal of Public Health, 2019 https://doi.org/10.17269/s41997-019-00209-0 Abstract Cannabis is now legal in Canada, yet important questions remain regarding how the provinces and territories are approaching cannabis education and messaging aimed at youth. Although widespread education and awareness campaigns are long considered cornerstones of substance use and related harm prevention, there is limited evidence to support the effectiveness of such campaigns. We continue to see examples of cannabis-related messaging that focus on risk and harm and often adopt a narrow [...]
Lire la suiteA Cross-Sectional Survey of Medical Cannabis Users : Patterns of Use and Perceived Efficacy Michelle Sexton, Carrie Cuttler, John S. Finnell, and Laurie K. Mischley Cannabis and Cannabinoid Research, 2016, Volume 1.1, 131-138 DOI: 10.1089/can.2016.0007 Abstract Background: The political climate around Cannabis as a medicine is rapidly changing. Legislators are adopting policies regarding appropriate medical applications, while the paucity of research may make policy decisions around conditions for which Cannabis is an effective medicine difficult. Methods: An anonymous online survey was developed to query medical Cannabis users about the conditions they use Cannabis to treat, their use patterns, perception of efficacy, and physical and mental health. [...]
Lire la suite